Follow Medasense’s accomplishments and news

FDA Commissioner Highlights Marketing Authorization of NOL Technology

In an update on the U.S. Food and Drug Administration’s efforts in combatting harm from opioids, FDA commissioner Robert M. Califf, MD highlighted the recent marketing authorization of NOL technology as an innovative solution for clinicians to personalize opioid-based analgesia in anesthetized patients.

Medasense is proud to be able to offer the cutting edge NOL-Nociception Level Index® technology to help U.S. patients suffer less from pain and the adverse effects of opioid medication.

Learn more at

Video Highlights

The essence of Medasense: Guiding critical care clinicians for optimal pain care

Meeting the challenge of intraoperative pain monitoring

Leading clinicians on the importance of monitoring the patient’s pain response level